✓ Editorial reviews of U.S. telehealth programs · Prices and dates shown on each page · Educational only — not medical advice
Drug Reference

Victoza

Released: Last reviewed:

Brand name for liraglutide 1.8 mg daily, FDA-approved for type 2 diabetes mellitus.

By Novo Nordisk
Researched By
Dr. Parmis
Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Last medically reviewed: November 20, 2026 · This page is informational and does not constitute medical advice.

Victoza overview

Brand name for liraglutide 1.8 mg daily, FDA-approved for type 2 diabetes mellitus.

Victoza at a glance

Manufacturer
Novo Nordisk
FDA status
FDA-approved

Related pages

Key facts, checked November 20, 2026

The Victoza label covers blood-sugar control in patients 10 and older with type 2 diabetes and lowering the risk of major cardiovascular events in adults with type 2 diabetes and established heart disease. It is a once-daily liraglutide injection and should not be used for type 1 diabetes. The weight-management form of liraglutide is Saxenda, at a higher dose. FDA drug-shortage data (openFDA) list liraglutide injection as in shortage, with an update dated October 14, 2026. FDA’s November 9, 2026 safety communication adds a NAION warning to all approved GLP-1 labels.